The DOI matches its Crossref record; 59 of the 59 references it cites were found in a registry or an index.
Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism
Abstract
Our previous studies have clearly shown that the angiogenic enzymes, matrix metalloproteinase (MMP) ‐2/9, are directly involved in human hepatic tumorigenesis and metastasis and suggest that the MMP‐2/9 inhibitors, which have dual inhibitory activi¬ties on enzyme activity and transcription, represent the best candidates for achieving tumor regression. Many anti‐cancer drugs have strong cellular cytotoxicity and side effects, indicating that strong anti‐cancer drugs that have no or minimal cytotoxicity and side effects need to be developed. The specific aim of the present study was to develop powerful anti‐cancer drugs with specific tumor regression and anti‐metastatic potential having the dual inhibitory activities of specific MMP‐2 and ‐9 enzyme activities and gene transcription at the molecular level. Caffeic acid (CA), a strong and selective MMP‐9 activity and transcription inhibitor, was isolated from the plant Euonymus alatus and its derivative, caffeic acid phenethyl ester (CAPE), was synthesized. CA and CAPE selectively inhibited MMP‐2 and ‐9 but not ‐1, ‐3, ‐7, or cathepsin K. Treatment of HepG2 cells with CA (100 μg/mL) and CAPE (5 μg/mL) suppressed phorbol 12‐myristate 13‐acetate (PMA) ‐in¬duced MMP‐9 expression by inhibiting the function of NF‐κB, but not AP‐1. We confirmed that CA and CAPE suppressed the growth of HepG2 tumor xenografts in nude mice in vivo. The subcutaneous and oral administrations of CA and CAPE significantly reduced the liver metastasis. These results confirm the therapeutic potential of the compounds and suggest that the antimetastatic and anti‐tumor effects of CA and CAPE are mediated through the selective suppression of MMP‐9 enzyme activity and transcriptional down‐regulation by the dual inhibition of NF‐κB as well as MMP‐9 catalytic activity.—Chung, T.‐W., Moon, S.‐K., Chang, Y.‐C., Ko, J.‐H., Lee, Y.‐C., Cho, G., Kim, S.‐H., Kim, J.‐G., Kim, C.‐H. Novel and therapeutic effect of caffeic acid and caffeic acid phenyl ester on hepatocarcinoma cells: complete regression of hepatoma growth and metastasis by dual mechanism. FASEBJ . 18, 1670–1681 (2004)
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Activators and target genes of Rel/NF-κB transcription factors
Pahl, H. L. (1999) · Oncogene · doi:10.1038/sj.onc.1203239 · Cited by 3,727
Matrix metalloproteinases and their inhibitors in connective tissue remodeling
Woessner, J. F. (1991) · The FASEB Journal · doi:10.1096/fasebj.5.8.1850705 · Cited by 3,282
Activators and Target Genes of Rel/NF-кB Transcription Factors: From Bench to Bedside
Loop, T., & Pahl, H. L. (2003) · Nuclear Factor кB · doi:10.1007/978-94-010-0163-2_1 · Cited by 3,169
Wang, C.-Y., Mayo, M. W., Korneluk, R. G., Goeddel, D. V., & Baldwin, A. S. (1998) · Science · doi:10.1126/science.281.5383.1680 · Cited by 2,711
Clinical Applications of Research on Angiogenesis
Folkman, J. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512283332608 · Cited by 2,264
Matrix Metalloproteinases: Biologic Activity and Clinical Implications
Nelson, A. R., Fingleton, B., Rothenberg, M. L., & Matrisian, L. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.5.1135 · Cited by 1,554
Phenolics in Food and Nutraceuticals
Shahidi, F., & Naczk, M. (2003) · CRC Press eBooks · doi:10.1201/9780203508732 · Cited by 1,496
NF-κB Controls Cell Growth and Differentiation through Transcriptional Regulation of Cyclin D1
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.8.5785 · Cited by 1,312
Natarajan, K., Singh, S., Burke, T. R., Grunberger, D., & Aggarwal, B. B. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.17.9090 · Cited by 1,139
Matrix metalloproteinases in angiogenesis: a moving target for therapeutic intervention
Stetler-Stevenson, W. G. (1999) · Journal of Clinical Investigation · doi:10.1172/jci6870 · Cited by 842
The I kappa B proteins: multifunctional regulators of Rel/NF-kappa B transcription factors.
Beg, A. A., & Baldwin, A. S. (1993) · Genes & Development · doi:10.1101/gad.7.11.2064 · Cited by 794
Matrix metalloproteinases and metastasis
Kleiner, D. E., & Stetler-Stevenson, W. G. (1999) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800051097 · Cited by 701
The AP-1 site and MMP gene regulation: What is all the fuss about?
Benbow, U., & Brinckerhoff, C. E. (1997) · Matrix Biology · doi:10.1016/s0945-053x(97)90026-3 · Cited by 520
Bond, M., Fabunmi, R. P., Baker, A. H., & Newby, A. C. (1998) · FEBS Letters · doi:10.1016/s0014-5793(98)01034-5 · Cited by 512
Molecular insights into cancer invasion: strategies for prevention and intervention.
Kohn, E. C., & Liotta, L. A. (1995) · PubMed · Cited by 496
Akt/PKB promotes cancer cell invasion via increased motility and metalloproteinase production
DOHOON, K., SUNHONG, K., HYONGJONG, K., SANG‐OH, Y., AN‐SIK, C., KYOUNG SANG, C., & JONGKYEONG, C. (2001) · The FASEB Journal · doi:10.1096/fj.01-0198com · Cited by 489
Preferential cytotoxicity on tumor cells by caffeic acid phenethyl ester isolated from propolis
Grunberger, D., Banerjee, R., Eisinger, K., Oltz, E. M., Efros, L., Caldwell, M., Estevez, V., & Nakanishi, K. (1988) · Experientia · doi:10.1007/bf01941717 · Cited by 487
Zandi, E., Chen, Y., & Karin, M. (1998) · Science · doi:10.1126/science.281.5381.1360 · Cited by 454
Nuclear transcription factor-κB as a target for cancer drug development
Garg, A., & Aggarwal, B. (2002) · Leukemia · doi:10.1038/sj.leu.2402482 · Cited by 441
Matrix metalloproteinase inhibition by green tea catechins
Demeule, M., Brossard, M., Pagé, M., Gingras, D., & Béliveau, R. (2000) · Biochimica et Biophysica Acta (BBA) - Protein Structure and Molecular Enzymology · doi:10.1016/s0167-4838(00)00009-1 · Cited by 429
MacDougall, J. R., & Matrisian, L. M. (1995) · Cancer and Metastasis Reviews · doi:10.1007/bf00690603 · Cited by 419
Michaluart, P., Masferrer, J. L., Carothers, A. M., Subbaramaiah, K., Zweifel, B. S., Koboldt, C. M., MESTRE, J. R., Grünberger, D., Sacks, P. G., Tanabe, T., et al. (1999) · PubMed · Cited by 373
Caffeic acid is a selective inhibitor for leukotriene biosynthesis
Yasuko, K., Tomohiro, N., Sei-Itsu, M., Ai-Na, L., Yasuo, F., & Takashi, T. (1984) · Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism · doi:10.1016/0005-2760(84)90287-x · Cited by 346
Tanaka, T., Kojima, T., Kawamori, T., Wang, A., Suzui, M., Okamoto, K., & Mori, H. (1993) · Carcinogenesis · doi:10.1093/carcin/14.7.1321 · Cited by 333
Food phenolics: Sources, chemistry, effects, applications
Griffiths, W. (1996) · Trends in Food Science & Technology · doi:10.1016/0924-2244(96)81226-x · Cited by 306
Chung, T., Lee, Y., & Kim, C. (2004) · The FASEB Journal · doi:10.1096/fj.03-1429fje · Cited by 288
Self-citationTamura, Y., Watanabe, F., Nakatani, T., Yasui, K., Fuji, M., Komurasaki, T., Tsuzuki, H., Maekawa, R., Yoshioka, T., Kawada, K., et al. (1998) · Journal of Medicinal Chemistry · doi:10.1021/jm9707582 · Cited by 284
Inhibitors of human immunodeficiency virus integrase.
Fesen, M. R., Kohn, K. W., Leteurtre, F., & Pommier, Y. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.6.2399 · Cited by 277
Scorilas, A., Karameris, A., Arnogiannaki, N., Ardavanis, A., Bassilopoulos, P., Trangas, T., & Talieri, M. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2001.1810 · Cited by 258
Gum, R., Wang, H., Lengyel, E., Juarez, J., & Boyd, D. (1997) · Oncogene · doi:10.1038/sj.onc.1200973 · Cited by 233
Arii, S., Mise, M., Harada, T., Furutani, M., Ishigami, S., Niwano, M., Mizumoto, M., Fukumoto, M., & Imamura, M. (1996) · Hepatology · doi:10.1002/hep.510240206 · Cited by 231
Meyer, R., Hatada, E. N., Hohmann, H. P., Haiker, M., Bartsch, C., Röthlisberger, U., Lahm, H. W., Schlaeger, E. J., van Loon, A. P., & Scheidereit, C. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.3.966 · Cited by 222
Eberhardt, W., Huwiler, A., Beck, K.-F., Walpen, S., & Pfeilschifter, J. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.10.5788 · Cited by 213
Nemunaitis, J. J., Poole, C. J., Primrose, J. M., et al. (1998) · PubMed · Cited by 211
Basset, P., Okada, A., Chenard, M.-P., Kannan, R., Stoll, I., Anglard, P., Bellocq, J.-P., & Rio, M.-C. (1997) · Matrix Biology · doi:10.1016/s0945-053x(97)90028-7 · Cited by 208
Frenkel, K., Wei, H., Bhimani, R. S., Ye, J., Zadunaisky, J. A., Huang, M., Ferraro, T., Conney, A. H., & Grünberger, D. (1993) · PubMed · Cited by 197
NF-κB activates Bcl-2 expression in t(14;18) lymphoma cells
Heckman, C. A., Mehew, J. W., & Boxer, L. M. (2002) · Oncogene · doi:10.1038/sj.onc.1205483 · Cited by 182
Ongoing trials with matrix metalloproteinase inhibitors
Brown, P. D. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.9.2167 · Cited by 167
Activation of NF-kappaB/Rel occurs early during neoplastic transformation of mammary cells
Kim, D. W. (2000) · Carcinogenesis · doi:10.1093/carcin/21.5.871 · Cited by 160
Sato, T., Koike, L., Miyata, Y., Hirata, M., Mimaki, Y., Sashida, Y., Yano, M., & Itô, A. (2002) · PubMed · Cited by 154
Anti-inflammatory Activity in Rats and Mice of Phenolic Acids Isolated from Scrophularia frutescens
Fernández, Á., Sáenz, M. T., & García, M. D. (1998) · Journal of Pharmacy and Pharmacology · doi:10.1111/j.2042-7158.1998.tb03332.x · Cited by 153
Tonn, J., Kerkau, S., Hanke, A., Bouterfa, H., Mueller, J. G., Wagner, S., Vince, G. H., & Roosen, K. (1999) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19990301)80:5<764::aid-ijc22>3.0.co;2-j · Cited by 142
Chung, T., Lee, Y., Ko, J., & Kim, C. (2003) · PubMed · Cited by 135
Self-citationArai, K., Lee, S., & Lo, E. H. (2003) · Glia · doi:10.1002/glia.10255 · Cited by 133
Nagaoka, T. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(02)00138-4 · Cited by 130
Lyons, J. G., BIRKEDAL‐HANSEN, B., Pierson, M. C., Whitelock, J. M., & Birkedal‐Hansen, H. (1993) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(17)46745-7 · Cited by 126
Aspirin and NS-398 inhibit hepatocyte growth factor-induced invasiveness of human hepatoma cells
Abiru, S., Nakao, K., Ichikawa, T., Migita, K., Shigeno, M., Sakamoto, M., Ishikawa, H., Hamasaki, K., Nakata, K., & Eguchi, K. (2002) · Hepatology · doi:10.1053/jhep.2002.32676 · Cited by 111
Kashiwada, Y., Nishizawa, M., Yamagishi, T., et al. (1995) · Journal of Natural Products · doi:10.1021/np50117a007 · Cited by 108
Lozonschi, L., Sunamura, M., Kobari, M., Egawa, S., Ding, L., & Matsuno, S. (1999) · PubMed · Cited by 107
BAY 12-9566, a novel inhibitor of matrix metalloproteinases with antiangiogenic activity.
Gatto, C., Rieppi, M., Borsotti, P., Innocenti, S., Ceruti, R., Drudis, T., Scanziani, E., Casazza, A. M., Taraboletti, G., & Giavazzi, R. (1999) · PubMed · Cited by 107
Lochter, A., & Bissell, M. J. (1999) · Apmis · doi:10.1111/j.1699-0463.1999.tb01535.x · Cited by 74
Nardini, M., Leonardi, F., Scaccini, C., & Virgili, F. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(00)00515-3 · Cited by 70
Hah, N., & Lee, S. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00788-5 · Cited by 70
Structure-activity relationship of caffeic acid analogues on xanthine oxidase inhibition.
Chan, W. S., Wen, P. C., & Chiang, H. C. (1995) · PubMed · Cited by 69
Maekawa, R., Maki, H., Yoshida, H., Hojo, K., Tanaka, H., Wada, T., Uchida, N., Takeda, Y., Kasai, H., Okamoto, H., et al. (1999) · PubMed · Cited by 59
Cholesteryl Ester Hydroperoxide Formation in Myoglobin-Catalyzed Low Density Lipoprotein Oxidation
Vieira, O. V., Laranjinha, J. A. N., Madeira, V. M. C., & Almeida, L. M. (1998) · Biochemical Pharmacology · doi:10.1016/s0006-2952(97)00470-x · Cited by 56
Inhibitory effect of methanol extract of Euonymus alatus on matrix metalloproteinase-9
Cha, B., Park, C.-J., Lee, D. G., et al. (2003) · Journal of Ethnopharmacology · doi:10.1016/s0378-8741(02)00373-2 · Cited by 49
Clinical Potential of Matrix Metalloprotease Inhibitors
Wojtowicz‐Praga, S. (1999) · Drugs in R&D · doi:10.2165/00126839-199901020-00001 · Cited by 46
Ploemen, J. H. T. M., van Ommen, B., de Haan, A., et al. (1993) · Food and Chemical Toxicology · doi:10.1016/0278-6915(93)90106-9 · Cited by 39
Cited by
Liu, G.-H., Qu, J., & Shen, X. (2008) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2008.01.002 · Cited by 697
Chemical and Pharmacological Aspects of Caffeic Acid and Its Activity in Hepatocarcinoma
Espíndola, K. M. M., Ferreira, R. G., Narvaez, L. E. M., Silva Rosario, A. C. R., da Silva, A. H. M., Silva, A. G. B., Vieira, A. P. O., & Monteiro, M. C. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00541 · Cited by 610
Eghbaliferiz, S., & Iranshahi, M. (2016) · Phytotherapy Research · doi:10.1002/ptr.5643 · Cited by 557
Minor components of pulses and their potential impact on human health
Campos-Vega, R., Loarca-Piña, G., & Oomah, B. D. (2010) · Food Research International · doi:10.1016/j.foodres.2009.09.004 · Cited by 530
An overview on the role of dietary phenolics for the treatment of cancers
Anantharaju, P. G., Gowda, P. C., Vimalambike, M. G., & Madhunapantula, S. V. (2016) · Nutrition Journal · doi:10.1186/s12937-016-0217-2 · Cited by 517
Metadata
- Authors
- Chung, T., Moon, S., Chang, Y., Ko, J., Lee, Y., Cho, G., Kim, S., Kim, J., & Kim, C.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2004-11
- Volume
- 18
- Issue
- 14
- Pages
- 1670-1681
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W1978272694
- Cited by
- 456
- References
- 59
- FWCI
- 6.37
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.